Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2021-05-19 Capital/Financing Update
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Proposed issue of Securities - NTI 5 pages 27.9KB
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a proposed issue of securities by Neurotech International Limited. It details the number and type of securities to be issued, the proposed issue date, conditions including shareholder approval, and the purpose of the issue (equity-based incentive to a director). The document is structured as a formal announcement to the ASX (Australian Securities Exchange) and does not contain financial statements or detailed financial analysis. It is not a report but an update on capital raising activities, specifically a placement or other type of issue of securities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive details about the proposed issue, confirming it is not merely a brief notice or report publication announcement.
2021-05-19 English
Appendix 2A 15 pages 222.9KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance of securities due to options being exercised or convertible securities being converted. The document is a regulatory announcement related to capital markets and securities listing, specifically an application for quotation of new securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement but a formal regulatory filing to the exchange. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP), as it relates to updates on company fundraising, financing activities, or capital structure changes.
2021-05-18 English
Update - Proposed issue of Securities - NTI 6 pages 30.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an 'Appendix 3B' filing submitted to the ASX by Neurotech International Limited. It details a proposed issue of securities (options) and serves as an update to a previous announcement regarding the issue date. Under the ASX listing rules, an Appendix 3B is the standard form for announcing new issues of securities, which falls under the 'Share Issue/Capital Change' category.
2021-05-11 English
Update - Proposed issue of Securities - NTI 6 pages 30.5KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Proposed issue of securities' and contains detailed information about a securities placement, including approval dates, number of securities, exercise price, and conditions related to the issue. It references ASX Listing Rules and includes updates to a previous announcement about the issue date. There is no financial performance data, earnings information, or management discussion. The content is focused on the company's capital raising activity and securities issuance. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the securities issue, not just a brief announcement or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2021-05-11 English
Appendix 2A 15 pages 218.7KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities to be quoted, and references to previous announcements such as Appendix 3B. The document is a regulatory form used to notify the exchange about new securities being listed, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information required for the quotation process. This type of document fits the category of Regulatory Filings (RNS) as it is a general regulatory announcement and does not fall under more specific categories like capital/financing update or share issue/capital change, which are typically announcements of actual transactions rather than the application for quotation itself.
2021-05-11 English
Results of Meeting 2 pages 130.2KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'Results of General Meeting' and details the outcomes of resolutions voted on by shareholders at a General Meeting held on 7 May 2021. It includes proxy vote counts and poll results for each resolution. There is no indication of it being a full report like an Annual Report or Interim Report, nor is it a transcript or presentation. The document is an official announcement of the voting results from a shareholder meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3509 characters, which is consistent with a concise announcement rather than a full report.
2021-05-06 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.